BSF Enterprise: A Year of Transformation and Growth in Tissue-Engineered Advanced Materials

As we delve into the financial results of BSF Enterprise PLC (GB:BSFA) for the full year 2024, it's clear that the company has undergone significant transformations, driven by operational achievements, strategic fundraising, and progress across its core subsidiaries. With a clear strategy in place, BSF is well-positioned to execute its goals in 2025, focusing on commercialization, partnerships, and sustainability to drive long-term value creation.



The year 2024 was marked by substantial progress across BSF's subsidiaries, advancing the company's mission to commercialize sustainable, tissue-engineered products. Some key highlights include:

1. 3DBT: The launch of CytoBoost™, a bioactive media additive targeting the biopharma downstream process, and the commercial expansion of City-Mix™ to support cost-effective production of cultivated meat.
2. Lab-Grown Leather: The development of the world's first 2mm-thick scaffold-free leather, marking a major technical breakthrough. Collaborations with luxury fashion brands are underway, and plans for a pilot production plant are in the works to scale commercial production.
3. Kerato: Securing a key licensing agreement with the University of Montreal for liquid cornea technology, a significant step towards in-situ corneal repair. Veterinary clinical trials in 2025 and the planning of human clinical trials in 2026/27 are on the roadmap.
4. BSF Enterprise (Hong Kong): Expanding the company's reach in Greater China, laying the foundation for local production of cultivated meat. This effort will increase BSF's access to the rapidly growing demand for sustainable protein in Asia.

Post-period, BSF raised £500,000 in an oversubscribed placement of new shares in December 2024. The funds will support the progress towards the commercialisation of CytoBoost™ (3DBT), developing plans for a pilot production of lab-grown leather (LGL), veterinary trials and clinical preparation (Kerato), and market expansion in Greater China (BSF Hong Kong). Additionally, BSF signed a strategic collaboration with Sartorius to drive cost-effective and sustainable biotech solutions.

BSF Enterprise PLC is a leading innovator in tissue-engineered advanced materials, focusing on the development and commercialization of cell-based tissue engineering solutions to deliver sustainable outcomes across various sectors. The company operates through subsidiaries such as 3DBT, Lab-Grown Leather, Kerato, and BSF Enterprise (Hong Kong), with a strategic emphasis on sustainable outcomes across sectors including biopharma, fashion, and food industries.

In conclusion, BSF Enterprise PLC's full year 2024 financial results demonstrate the company's commitment to innovation, sustainability, and growth. With a strong focus on commercialization, partnerships, and sustainability, BSF is well-positioned to continue its transformation and drive long-term value creation in the tissue-engineered advanced materials sector.